Information Provided By: 
Fly News Breaks for May 4, 2018
PBYI
May 4, 2018 | 07:55 EDT
An analysis of 90 oncology drug launches indicates that products with U.S. sales of at least $200M in the first full calendar year have a greater than 50% probability of reaching $1B-plus sales, Citi analyst Yigal Nochomovitz tells investors in a research note. He believes the analysis supports his view that $1.1B of U.S. sales for Nerlynx by 2024 is an achievable goal, based on Puma Biotechnology's 2018 guidance of $175M-$200M. The analyst keeps a Buy rating on the shares.
News For PBYI From the Last 2 Days
There are no results for your query PBYI
